These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

365 related items for PubMed ID: 29125702

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. PTL401, a New Formulation Based on Pro-Nano Dispersion Technology, Improves Oral Cannabinoids Bioavailability in Healthy Volunteers.
    Atsmon J, Cherniakov I, Izgelov D, Hoffman A, Domb AJ, Deutsch L, Deutsch F, Heffetz D, Sacks H.
    J Pharm Sci; 2018 May; 107(5):1423-1429. PubMed ID: 29287930
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A Novel Self-Emulsifying Drug Delivery System (SEDDS) Based on VESIsorb® Formulation Technology Improving the Oral Bioavailability of Cannabidiol in Healthy Subjects.
    Knaub K, Sartorius T, Dharsono T, Wacker R, Wilhelm M, Schön C.
    Molecules; 2019 Aug 16; 24(16):. PubMed ID: 31426272
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration.
    Karschner EL, Darwin WD, Goodwin RS, Wright S, Huestis MA.
    Clin Chem; 2011 Jan 16; 57(1):66-75. PubMed ID: 21078841
    [Abstract] [Full Text] [Related]

  • 11. A phase I study to assess the single and multiple dose pharmacokinetics of THC/CBD oromucosal spray.
    Stott CG, White L, Wright S, Wilbraham D, Guy GW.
    Eur J Clin Pharmacol; 2013 May 16; 69(5):1135-47. PubMed ID: 23179176
    [Abstract] [Full Text] [Related]

  • 12. Tetrahydrocannabinol/Cannabidiol Oromucosal Spray in Patients With Multiple Sclerosis: A Pilot Study on the Plasma Concentration-Effect Relationship.
    Contin M, Mancinelli L, Perrone A, Sabattini L, Mohamed S, Scandellari C, Foschi M, Vacchiano V, Lugaresi A, Riva R.
    Clin Neuropharmacol; 2018 May 16; 41(5):171-176. PubMed ID: 30024443
    [Abstract] [Full Text] [Related]

  • 13. A pilot safety, tolerability and pharmacokinetic study of an oro-buccal administered cannabidiol-dominant anti-inflammatory formulation in healthy individuals: a randomized placebo-controlled single-blinded study.
    Vitetta L, Butcher B, Henson JD, Rutolo D, Hall S.
    Inflammopharmacology; 2021 Oct 16; 29(5):1361-1370. PubMed ID: 34357480
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Examination of a New Delivery Approach for Oral Cannabidiol in Healthy Subjects: A Randomized, Double-Blinded, Placebo-Controlled Pharmacokinetics Study.
    Patrician A, Versic-Bratincevic M, Mijacika T, Banic I, Marendic M, Sutlović D, Dujić Ž, Ainslie PN.
    Adv Ther; 2019 Nov 16; 36(11):3196-3210. PubMed ID: 31512143
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetic and behavioural profile of THC, CBD, and THC+CBD combination after pulmonary, oral, and subcutaneous administration in rats and confirmation of conversion in vivo of CBD to THC.
    Hložek T, Uttl L, Kadeřábek L, Balíková M, Lhotková E, Horsley RR, Nováková P, Šíchová K, Štefková K, Tylš F, Kuchař M, Páleníček T.
    Eur Neuropsychopharmacol; 2017 Dec 16; 27(12):1223-1237. PubMed ID: 29129557
    [Abstract] [Full Text] [Related]

  • 17. Examining the Systemic Bioavailability of Cannabidiol and Tetrahydrocannabinol from a Novel Transdermal Delivery System in Healthy Adults: A Single-Arm, Open-Label, Exploratory Study.
    Varadi G, Zhu Z, Crowley HD, Moulin M, Dey R, Lewis ED, Evans M.
    Adv Ther; 2023 Jan 16; 40(1):282-293. PubMed ID: 36308640
    [Abstract] [Full Text] [Related]

  • 18. Effect of tetrahydrocannabinol:cannabidiol oromucosal spray on activities of daily living in multiple sclerosis patients with resistant spasticity: a retrospective, observational study.
    Mallada Frechín J.
    Neurodegener Dis Manag; 2018 Jun 16; 8(3):151-159. PubMed ID: 29851356
    [Abstract] [Full Text] [Related]

  • 19. Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: A randomized, double-blind, controlled trial.
    Schoedel KA, Szeto I, Setnik B, Sellers EM, Levy-Cooperman N, Mills C, Etges T, Sommerville K.
    Epilepsy Behav; 2018 Nov 16; 88():162-171. PubMed ID: 30286443
    [Abstract] [Full Text] [Related]

  • 20. Application device for THC:CBD oromucosal spray in the management of resistant spasticity: pre-production testing.
    Montero-Escribano P, Vila Silván C.
    Expert Rev Med Devices; 2019 Sep 16; 16(9):835-840. PubMed ID: 31393179
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.